Business Wire

Xsolla Announces Drops, a New Campaign-based Community Engagement Tool

Share

Xsolla, a global video game commerce company, announced today that they are launching a new tool to augment their existing Xsolla Partner Network solution, called Xsolla Drops. Xsolla Partner Network is an efficient solution for game developers and publishers to create and scale performance-based influencer and affiliate programs. Xsolla Drops provides an added layer of marketing support for game developers to increase user acquisition and incremental sales by streamlining the ability to promote their digital items, including virtual currencies, skins, NFTs, game keys, premium subscriptions, and more.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230523005467/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Xsolla Drops (Graphic: Business Wire)

"Drops gives game developers and publishers the ability to build and reward their gaming audience easily," said Alexander Menshikov, Business Head at Xsolla. "We are helping game developers reward their fans, explore new user acquisition methods, and strengthen long-term engagement with a game's current player base by offering exclusive in-game items and unique experiences. With Drops, developers will create game-specific campaigns with targeted audiences, delivering a personalized experience on a custom landing page with no code required."

As user acquisition costs rise, developer budgets are taking a hit as they attempt to navigate which marketing channels are the most effective. Drops takes a multi-tiered campaign approach to this issue by bringing the thrill of game discovery back to the players, creating inherent value for creators, and raising a game's overall brand awareness.

This comprehensive, new marketing tool solves the challenge of the rising costs of acquiring, engaging, and retaining players with branded websites and close collaboration with influencers, artists, esports pro gamers, celebrities, and renowned agencies.

"We were thrilled with the results of our Drops campaign with Xsolla," said Scott Robinson, Owner of SprintGP. "The onboarding process was easy and only took a few hours from start to finish. All we needed to do was to fill out the form, upload game design assets, and provide redemption instructions for players to get a reward. Xsolla handled the rest, including web page development and marketing setup. We doubled our user base in less than 24 hours and saw a 300% increase in website traffic. We highly recommend Xsolla's Drops tool to any game developer looking for new ways to drive user acquisition and engagement."

For more information about Xsolla Drops, please visit https://xsolla.pro/drops

About Xsolla

Xsolla is a global video game commerce company with a robust and powerful set of tools and services designed specifically for the video game industry. Since its founding in 2005, Xsolla has helped thousands of game developers and publishers of all sizes fund, market, launch and monetize their games globally and across multiple platforms. As an innovative leader in game commerce, Xsolla’s mission is to solve the inherent complexities of global distribution, marketing, and monetization to help our partners reach more geographies, generate more revenue and create relationships with gamers worldwide. Headquartered and incorporated in Los Angeles, California, with offices in Berlin, Seoul, Beijing, Kuala Lumpur, and cities around the world, Xsolla supports major gaming titles like Valve, Twitch, Roblox, Ubisoft, Epic Games, Take-Two, KRAFTON, Nexters, NetEase, Playstudios, Playrix, miHoYo, and more.

For additional information and to learn more, please visit: xsolla.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact
Derrick Stembridge
Global Director of Public Relations, Xsolla
d.stembridge@xsolla.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Connections, Local Flavors, and Luxurious Experiences Top the 2026 Bacardi Cocktail Trends Report17.11.2025 14:00:00 EET | Press release

The five defining trends set to reshape cocktail culture and the spirits industry in 2026 are highlighted in the seventh annual Bacardi Cocktail Trends Report. The Report released by Bacardi Limited, the largest privately held international spirits company, in partnership with The Future Laboratory (TFL), draws on data from Bacardi-led and third-party research, consumer surveys, bartender interviews and TFL’s trend forecasting to uncover the forces shaping cocktail experiences, flavor innovation, and drinking culture in the year ahead. The Report also reveals the cocktails which are set to be the most popular in 2026 and trends for younger Legal Drinking Age (LDA) consumers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117678098/en/ The 7th annual Bacardi Cocktail Trends Report unveils what and how people will be drinking in 2026. “Gen Z isn’t drinking less, they’re simply drinking earlier, lighter, and with more intent

AdvanCell Appoints Philina Lee, PhD as Chief Executive Officer to Lead US Expansion and Drive Global Growth17.11.2025 14:00:00 EET | Press release

AdvanCell Pty Ltd (“AdvanCell”), a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced the appointment of Philina Lee, PhD as Chief Executive Officer and member of the Board of Directors. Dr Lee will head AdvanCell’s US expansion, accelerating clinical, manufacturing, and partnership activities to advance lead clinical candidate 212Pb-ADVC001 and the company’s innovative radiopharmaceutical portfolio. She will assume her role from January 1, 2026, and will be based at the company’s new US headquarters near Boston/Cambridge, MA. “Philina brings a rare combination of global commercial leadership, deep radiopharmaceutical expertise, and an outstanding record of building high growth organizations and high-performance teams,” said Andrew Kay, Chair of AdvanCell. “Her leadership and experience positions AdvanCell to drive its next phase of growth, with the United States now a major strategic focus as the company advances 212Pb

MSCI Announces Baer Pettit to Retire as President17.11.2025 14:00:00 EET | Press release

MSCI Inc. (NYSE: MSCI), a leading provider of critical decision support tools and services for the global investment community, announced that C.D. Baer Pettit, President and Chief Operating Officer (COO), and a member of the Board of Directors, has informed the company that he will retire next year after more than 25 years in senior leadership roles. Mr. Pettit will continue to serve as President and a Director until March 1, 2026, and will remain as an advisor to the company for a period of time to ensure a smooth transition. Mr. Pettit joined MSCI in 2000 and has served in numerous senior leadership roles, including heading Client Coverage, Marketing and Index. He was appointed COO in 2015 and President in 2017, overseeing all products and operations, and he joined the Board of Directors in 2023. “Baer has been my longtime business partner, and he has played a pivotal role in shaping MSCI’s strategy and success,” said MSCI Chairman and CEO Henry Fernandez. “I would like to thank Bae

Arada to Acquire Majority Stake in £2.5bn Thameside West Development, Unlocking One of London’s Largest and Most Connected New Waterfront Neighbourhoods17.11.2025 13:58:00 EET | Press release

Arada, the UAE’s fastest-growing master developer, announces that it has agreed the acquisition of an 80% stake in Thameside West, a landmark waterfront mixed-use development located at the western end of London’s Royal Docks. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117374964/en/ HH Sheikh Sultan bin Ahmed Al Qasimi, Chairman of Arada (centre) with members of the Arada and Keystone executive teams (Photo: AETOSWire) Master-planned by Foster + Partners, the vibrant new urban destination will deliver at least 5,000 homes, with half of the site dedicated to green space and a kilometre of active waterfront. Boasting unrivalled transport links, the integration of air, road, rail, river and tunnel links makes this one of the most connected sites in London. Spread over a 47-acre area – twice the size of the Hudson Yards mixed-use development in New York - Thameside West represents one of Europe’s largest and most strategi

Positive Phase 3 Results Support ZIIHERA ® as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA ® and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma17.11.2025 13:00:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive top-line results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with or without PD-1 inhibitor TEVIMBRA® (tislelizumab), as first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA), including cancers of the stomach, gastroesophageal junction, and esophagus. Both ZIIHERA plus TEVIMBRA and chemotherapy and ZIIHERA plus chemotherapy demonstrated clinically meaningful and highly statistically significant improvements in progression-free survival (PFS) compared to the control arm, trastuzumab plus chemotherapy. ZIIHERA plus TEVIMBRA and chemotherapy also demonstrated clinically meaningful and statistically significant improvements in overall survival (OS), and ZIIHERA plus chemotherapy demonstrated a clinically meaningful eff

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye